Business Description
Sichuan Zitonggong Pharmaceutical Co Ltd
ISIN : CNE100004MP0
Total Employee Number:
382Compare
Compare
Traded in other countries / regions
920566.China IPO Date
2021-08-13Description
Sichuan Zitonggong Pharmaceutical Co Ltd is a high-tech enterprise focusing on the R&D, production, and marketing of tablets, hard capsules, liniments, powders, and ointments. It has developed a number of drug varieties, such as Citicoline Sodium Tablets and Rizatriptan Benzoate Capsules.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.38 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.13 | |||||
Interest Coverage | 121.49 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 9.17 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1 | |||||
3-Year EBITDA Growth Rate | -3.7 | |||||
3-Year EPS without NRI Growth Rate | -2.8 | |||||
3-Year FCF Growth Rate | -13.3 | |||||
3-Year Book Growth Rate | 5.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.69 | |||||
9-Day RSI | 45.57 | |||||
14-Day RSI | 47.5 | |||||
3-1 Month Momentum % | -4.15 | |||||
6-1 Month Momentum % | -17.35 | |||||
12-1 Month Momentum % | -28.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.31 | |||||
Quick Ratio | 7.38 | |||||
Cash Ratio | 5.78 | |||||
Days Inventory | 218.49 | |||||
Days Sales Outstanding | 79.01 | |||||
Days Payable | 84.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.04 | |||||
Dividend Payout Ratio | 0.69 | |||||
3-Year Dividend Growth Rate | -26.3 | |||||
Forward Dividend Yield % | 2.04 | |||||
5-Year Yield-on-Cost % | 2.04 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 2.05 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.41 | |||||
Operating Margin % | 21.93 | |||||
Net Margin % | 19.45 | |||||
EBITDA Margin % | 22.51 | |||||
FCF Margin % | 13.97 | |||||
OCF Margin % | 28.21 | |||||
ROE % | 10.23 | |||||
ROA % | 8.85 | |||||
ROIC % | 15.53 | |||||
3-Year ROIIC % | -1.37 | |||||
ROC (Joel Greenblatt) % | 41.66 | |||||
ROCE % | 10.98 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.59 | |||||
PE Ratio without NRI | 16.88 | |||||
Shiller PE Ratio | 16.68 | |||||
Price-to-Owner-Earnings | 26.6 | |||||
PS Ratio | 3.21 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 2.05 | |||||
Price-to-Free-Cash-Flow | 23.94 | |||||
Price-to-Operating-Cash-Flow | 11.49 | |||||
EV-to-EBIT | 10.78 | |||||
EV-to-EBITDA | 10.78 | |||||
EV-to-Revenue | 2.43 | |||||
EV-to-FCF | 17.37 | |||||
Price-to-GF-Value | 0.93 | |||||
Price-to-Projected-FCF | 1.18 | |||||
Price-to-Graham-Number | 1.24 | |||||
| Price-to-Net-Current-Asset-Value | 3.44 | |||||
| Price-to-Net-Cash | 5.73 | |||||
Earnings Yield (Greenblatt) % | 9.28 | |||||
FCF Yield % | 4.32 | |||||
Forward Rate of Return (Yacktman) % | -5.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sichuan Zitonggong Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 437.668 | ||
| EPS (TTM) (Â¥) | 0.59 | ||
| Beta | 1.134 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 0.75 | ||
| Volatility % | 25.8 | ||
| 14-Day RSI | 47.5 | ||
| 14-Day ATR (Â¥) | 0.341567 | ||
| 20-Day SMA (Â¥) | 9.9485 | ||
| 12-1 Month Momentum % | -28.51 | ||
| 52-Week Range (Â¥) | 8.88 - 14.09 | ||
| Shares Outstanding (Mil) | 144.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sichuan Zitonggong Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sichuan Zitonggong Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.200000 Cash Dividend | 2026-06-29 | 9.27 (-2.73%) | ||
| CNY 0.200000 Cash Dividend | 2025-07-23 | 14.29 (-0.07%) | ||
| 2:1 Stock Split | 2022-06-14 | 7.87 (+2.88%) |
Show
Entries
Sichuan Zitonggong Pharmaceutical Co Ltd Frequently Asked Questions
What is Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566)'s stock price today?
The current price of BJSE:920566 is ¥9.79. The 52 week high of BJSE:920566 is ¥14.09 and 52 week low is ¥8.88.
When is next earnings date of Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566)?
The next earnings date of Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566) is .
Does Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566) pay dividends? If so, how much?
The Dividend Yield %  of Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566) is 2.04% (As of Today), Highest Dividend Payout Ratio of Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566) was 0.81. The lowest was 0.23. And the median was 0.44. The  Forward Dividend Yield % of Sichuan Zitonggong Pharmaceutical Co Ltd(BJSE:920566) is 2.04%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sichuan Zitonggong Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers